Genentech co-pay programs provide financial assistance to eligible commercially insured patients to help with their co-pays, co-insurance, or other out-of-pocket (OOP) costs.
- ACTEMRA® (tocilizumab) CO-PAY PROGRAM
- CELLCEPT® (mycophenolate mofetil) CO-PAY PROGRAM
- ENSPRYNG® (satralizumab-mwge) CO-PAY PROGRAM
- Evrysdi® (risdiplam) CO-PAY PROGRAM
- HEMLIBRA® (emicizumab-kxwh) CO-PAY PROGRAM
- OCREVUS® (ocrelizumab) CO-PAY PROGRAM
- PiaSky™ (crovalimab-akkz) CO-PAY PROGRAM
- Pulmozyme® (dornase alfa) Inhalation Solution CO-PAY PROGRAM
- Rituxan® (rituximab) Immunology CO-PAY PROGRAM
- XOLAIR® (omalizumab) for subcutaneous use CO-PAY PROGRAM
- ALECENSA® (alectinib)
- Avastin® (bevacizumab)
- COLUMVI® (glofitamab-gxbm)
- COTELLIC® (cobimetinib)
- Erivedge® (vismodegib)
- GAZYVA® (obinutuzumab)
- Herceptin® (trastuzumab)
- Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk)
- Itovebi™ (inavolisib)
- KADCYLA® (ado-trastuzumab emtansine)
- LUNSUMIO® (mosunetuzumab-axgb)
- PERJETA® (pertuzumab)
- PHESGO® (pertuzumab, trastuzumab, and hyaluronidase- zzxf) injection, for subcutaneous use
- POLIVY® (polatuzumab vedotin-piiq)
- RITUXAN® (rituximab)
- RITUXAN HYCELA® (rituximab/hyaluronidase human)
- ROZLYTREK® (entrectinib)
- TECENTRIQ® (atezolizumab)
- TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs)
- VENCLEXTA® (venetoclax tablets)
- ZELBORAF® (vemurafenib)
- LUCENTIS® (ranibizumab injection)
- SUSVIMO® (ranibizumab injection)
- VABYSMO® (faricimab-svoa)
Eligibility criteria and benefit limits apply. Not valid for patients whose prescriptions are reimbursed under any federal or state government programs to pay for their medicine and/or administration of their Genentech medicine. Patients must be taking the Genentech medicine for an FDA-approved indication. Please visit the Co-pay Program website for the full list of Terms and Conditions.